



## Clinical trial results:

### A Phase I Pharmacokinetic and Safety Study of Tocilizumab (TCZ) in Patients Less Than 2 Years Old with Active Systemic Juvenile Idiopathic Arthritis (sJIA)

#### Summary

EudraCT number	2015-000435-33
Trial protocol	DE HU BE ES PL GB FR
Global end of trial date	13 July 2017

#### Results information

Result version number	v3 (current)
This version publication date	25 January 2018
First version publication date	12 February 2017
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	NP25737
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01455701
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com
Scientific contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	28 July 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	28 July 2016
Global end of trial reached?	Yes
Global end of trial date	13 July 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the pharmacokinetics of tocilizumab over 12 weeks in participants less than 2 years of age with sJIA.

Protection of trial subjects:

The investigator ensured that this study was conducted in full conformance with the principles of the "Declaration of Helsinki" or with the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. The study fully adhered to the principles outlined in current "Guideline for Good Clinical Practice" International Conference on Harmonization (ICH) Tripartite Guideline or with local law if it afforded greater protection to the participant.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 October 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	Argentina: 1
Country: Number of subjects enrolled	Hungary: 1
Country: Number of subjects enrolled	United States: 5
Worldwide total number of subjects	11
EEA total number of subjects	5

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	11

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Total 11 participants were enrolled, all of which were treated by tocilizumab.

### Period 1

Period 1 title	Overall Study
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Tocilizumab
------------------	-------------

Arm description:

Participants received tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants had the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants received tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reached 2 years of age or had been treated for one year from baseline, whichever was longer.

Arm type	Experimental
Investigational medicinal product name	Tocilizumab
Investigational medicinal product code	RO4877533
Other name	RoActemra; Actemra
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tocilizumab was administered as indicated in the arm description.

Number of subjects in period 1	Tocilizumab
Started	11
Completed	7
Not completed	4
Adverse event	4

### Period 2

Period 2 title	Optional Extension Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Arm title	Tocilizumab
-----------	-------------

### Arm description:

Participants received tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants had the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants received tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reached 2 years of age or had been treated for one year from baseline, whichever was longer.

Arm type	Experimental
Investigational medicinal product name	Tocilizumab
Investigational medicinal product code	RO4877533
Other name	RoActemra; Actemra
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

### Dosage and administration details:

Tocilizumab was administered as indicated in the arm description.

Number of subjects in period 2	Tocilizumab
Started	7
Completed	5
Not completed	2
Consent withdrawn by subject	1
Adverse event, non-fatal	1

## Baseline characteristics

### Reporting groups

Reporting group title	Tocilizumab
-----------------------	-------------

Reporting group description:

Participants received tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants had the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants received tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reached 2 years of age or had been treated for one year from baseline, whichever was longer.

Reporting group values	Tocilizumab	Total	
Number of subjects	11	11	
Age Categorical Units: Subjects			
Infants and toddlers (28 days - 23 months)	11	11	
Age Continuous Units: months arithmetic mean standard deviation	15.9 ± 4.0	-	
Gender Categorical Units: Subjects			
Female	7	7	
Male	4	4	

## End points

### End points reporting groups

Reporting group title	Tocilizumab
-----------------------	-------------

Reporting group description:

Participants received tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants had the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants received tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reached 2 years of age or had been treated for one year from baseline, whichever was longer.

Reporting group title	Tocilizumab
-----------------------	-------------

Reporting group description:

Participants received tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants had the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants received tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reached 2 years of age or had been treated for one year from baseline, whichever was longer.

### Primary: Maximum Serum Concentration (Cmax) of Tocilizumab

End point title	Maximum Serum Concentration (Cmax) of Tocilizumab <sup>[1]</sup>
-----------------	--

End point description:

Pharmacokinetic profile of tocilizumab was evaluated in terms of model predicted Cmax at steady state. Pharmacokinetic-evaluable population included all participants who provided at least one serum pharmacokinetic sample with valid concentration data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-infusion (Hour 0) on Days 1, 15, 29, 43, 57, 71, and 85; at the end of infusion on Days 1, 29 and 71; and anytime on Days 8, 36, and 78 (infusion length = 1 hour)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this study.

End point values	Tocilizumab			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: micrograms per milliliter (mcg/mL)				
arithmetic mean (standard deviation)	288 (± 40.4)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Minimum Serum Concentration (Cmin) of Tocilizumab

End point title	Minimum Serum Concentration (Cmin) of Tocilizumab <sup>[2]</sup>
-----------------	--

End point description:

Pharmacokinetic profile of tocilizumab was evaluated in terms of observed Cmin at day 85.

Pharmacokinetic-evaluable population.

End point type	Primary
----------------	---------

End point timeframe:

Pre-infusion (Hour 0) on day 85; (infusion length = 1 hour)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this study.

<b>End point values</b>	Tocilizumab			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mcg/mL				
arithmetic mean (standard deviation)	69.21 (± 42.02)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Model predicted Area Under the Serum Concentration-Time Curve from Time Zero to End of Dosing (AUCtau) of Tocilizumab

End point title	Model predicted Area Under the Serum Concentration-Time Curve from Time Zero to End of Dosing (AUCtau) of Tocilizumab <sup>[3]</sup>
-----------------	--

End point description:

AUCtau is the model-predicted area under the tocilizumab serum concentration versus time curve from time zero to the end of dosing interval (2 weeks). Pharmacokinetic-evaluable population.

End point type	Primary
----------------	---------

End point timeframe:

Pre-infusion (Hour 0) on Days 1, 15, 29, 43, 57, 71, and 85; at the end of infusion on Days 1, 29 and 71; and anytime on Days 8, 36, and 78 (infusion length = 1 hour)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this study.

<b>End point values</b>	Tocilizumab			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: micrograms*day per milliliter				
arithmetic mean (standard deviation)	947.4 (± 231.2)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Adverse Events (AEs) and Serious AEs



End point title	Number of Participants With Adverse Events (AEs) and Serious AEs
End point description: Number of participants with categorized AEs and serious AEs is reported. Detailed information of AEs is provided in the AEs section.	
End point type	Secondary
End point timeframe: Baseline up to end of the main evaluation period (Week 12)	

<b>End point values</b>	Tocilizumab			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: participants				
AE with fatal outcome	0			
Serious AE	3			
Serious AE leading to withdrawal	3			
Serious AE leading to dose modification	0			
Related Serious AE	3			
AE leading to withdrawal	4			
AE leading to dose modification	1			
Related AE	6			
Related AE leading to withdrawal	4			
Related AE leading to dose modification	1			
Total number of patients with at least one AE	10			
Total number of deaths	0			
Total number of patients withdrawn due an AE	4			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to end of the study (up week 52)

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

### Reporting groups

Reporting group title	Tocilizumab
-----------------------	-------------

Reporting group description:

Participants received tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) for up to 10 weeks (a total of 6 infusions including one at baseline visit) in main evaluation period (12-week period) and 12 mg/kg every Q2W from week 12 until participant reached 2 years of age or had been treated for one year from baseline in optional extension period.

Serious adverse events	Tocilizumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 11 (45.45%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Investigations			
Transaminases increased			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Histiocytosis haematophagic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Urticaria			

subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Juvenile idiopathic arthritis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Hand-foot-and-mouth disease			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Tocilizumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 11 (72.73%)		
Investigations			
Transaminases increased			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Neutrophil count decreased			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			

Arthropod bite subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Blood and lymphatic system disorders Neutropenia subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 4		
Thrombocytopenia subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2		
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
General disorders and administration site conditions Injection site reaction subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Hypocomplementaemia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Gastrointestinal disorders Chapped lips subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Dental caries subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Vomiting subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 4		
Diarrhoea			

subjects affected / exposed occurrences (all)  Enteritis subjects affected / exposed occurrences (all)	2 / 11 (18.18%)  5  1 / 11 (9.09%)  1		
Respiratory, thoracic and mediastinal disorders Allergic respiratory symptom subjects affected / exposed occurrences (all)	1 / 11 (9.09%)  1		
Skin and subcutaneous tissue disorders Dermatitis subjects affected / exposed occurrences (all)  Rash subjects affected / exposed occurrences (all)  Eczema subjects affected / exposed occurrences (all)  Urticaria subjects affected / exposed occurrences (all)	1 / 11 (9.09%)  1  3 / 11 (27.27%)  4  1 / 11 (9.09%)  1  1 / 11 (9.09%)  1		
Endocrine disorders Cushingoid subjects affected / exposed occurrences (all)	2 / 11 (18.18%)  2		
Musculoskeletal and connective tissue disorders Still's disease subjects affected / exposed occurrences (all)	1 / 11 (9.09%)  1		
Infections and infestations Ear infection subjects affected / exposed occurrences (all)  Respiratory tract infection viral	2 / 11 (18.18%)  2		

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	6 / 11 (54.55%)		
occurrences (all)	9		
Enterovirus infection			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Exanthema subitum			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Gastroenteritis norovirus			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Gastroenteritis viral			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
Otitis externa			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Otitis media			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Parotitis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Viral pharyngitis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Viral rhinitis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Viral upper respiratory tract infection			

subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 6		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hypercalcaemia			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Hyperlipidaemia			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Vitamin D deficiency			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 October 2011	Protocol was amended for removal of sampling for anti-tocilizumab antibody, tocilizumab pharmacokinetics, and soluble interleukin-6 receptor (sIL-6R) at Week 18.
30 January 2012	Protocol was amended for making steroid tapering non-mandatory to remain stable for 6 weeks.
29 October 2014	Protocol was amended to change the time between diagnosis of sJIA and treatment with biologics from a 3-month delay to a 1-month delay.
01 June 2015	Protocol was amended to address concerns raised in the protocol review during the voluntary harmonization procedure in Europe. An exclusion criterion was amended to clarify that previous history of significant allergic or infusion reactions to any of the excipients listed in tocilizumab product labeling documents was part of this exclusion criterion.
10 February 2016	Protocol was amended mainly to clarify an inclusion criterion that it was intended to refer to the 1 month period of symptoms subsequent to the diagnosis of sJIA, before being considered for treatment with a biologic therapy, consistent with the updated American College of Rheumatology (ACR) recommendations for the treatment of sJIA that outlined the use of biologic therapy.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported